The Silent Burden of Menopause: Why Genitourinary Syndrome Deserves Frontline Attention
There’s a pattern many clinicians recognize but don’t always name out loud.
A patient in her 50s comes in for “recurrent UTIs.” Another mentions discomfort with intimacy, almost as an aside. A third has persistent vaginal irritation that’s been treated repeatedly as infection—with little success.
Different complaints. Same underlying physiology.
This is genitourinary syndrome of menopause (GSM)—a chronic, progressive condition that affects a substantial proportion of women, yet remains underdiagnosed, under-discussed, and often mismanaged.
What GSM Actually Is (and Isn’t)
The term GSM was introduced in 2014 by American College of Obstetricians and Gynecologists to replace the narrower concept of “vulvovaginal atrophy.” The goal was to reflect reality more accurately: this is not just a vaginal issue.
It’s a multisystem hypoestrogenic syndrome affecting:
Vulvovaginal tissue
Lower urinary tract
Sexual function
Typical symptoms include:
Vaginal dryness, burning, irritation
Dyspareunia and decreased lubrication
Urinary urgency, dysuria
Recurrent urinary tract infections
Prevalence estimates range widely—from ~27% to over 80% of postmenopausal women—depending on how actively you ask and how symptoms are defined (Crandall et al., JAMA 2023; Faubion et al., Mayo Clin Proc 2017).
The key point: this is common, persistent, and not self-limited.
The Physiology Is Straightforward. The Clinical Impact Is Not.
At its core, GSM is driven by declining estrogen (and to some extent androgen) levels.
That hormonal shift leads to:
Thinning of the vaginal epithelium
Loss of elasticity and rugae
Reduced blood flow and lubrication
Increased vaginal pH (>4.5)
Over time, these changes alter the microbiome, weaken mucosal defenses, and contribute to urinary symptoms and recurrent infections (NAMS 2020; AAFP 2020).
This is not cosmetic. It’s structural and functional.
And unlike vasomotor symptoms, GSM does not improve with time. It progresses.
Why We Miss It
Two reasons, consistently:
1. Patients don’t volunteer symptoms
There’s embarrassment, normalization (“this is just aging”), or lack of awareness that treatment exists.
2. Clinicians don’t consistently screen
Unless you ask directly, you won’t hear it.
A simple shift in practice changes detection rates dramatically:
“Any vaginal dryness or discomfort?”
“Any pain with intercourse?”
“Any urinary urgency or recurrent infections?”
These questions should be as routine as asking about hot flashes.
Diagnosis: Clinical, Not Complicated
GSM is a clinical diagnosis.
On exam, you may see:
Pale, thin epithelium
Loss of vaginal rugae
Introital narrowing
Increased fragility
No biopsy is required unless something atypical is present (Kaufman et al., J Urol 2025).
What matters most is connecting symptoms to physiology.
Treatment: Practical, Stepwise, and Highly Effective
Management should be individualized, but there is a clear evidence-based framework.
1. Start Simple (and Don’t Skip This)
For mild symptoms:
Vaginal moisturizers: 1–3× per week (not just before intercourse)
Lubricants: as needed
Some data suggest these can approach the efficacy of hormonal therapies in mild cases (Danan et al., Ann Intern Med 2024).
Clinical pearl: Many patients underuse these or use them incorrectly. Education alone improves outcomes.
2. Escalate When Needed: Local Hormonal Therapy
When symptoms persist, low-dose vaginal estrogen is the gold standard.
Forms include:
Estradiol tablets (10 mcg)
Creams
Vaginal rings
Expected outcomes:
~60–80% improvement in dryness and dyspareunia
Improved tissue integrity and pH normalization
Importantly:
Minimal systemic absorption
No progestogen required for endometrial protection at low doses
(NAMS 2020; AUA/SUFU/AUGS 2025)
3. Alternatives Worth Knowing
For patients who prefer non-estrogen options or need alternatives:
Vaginal DHEA (prasterone 6.5 mg daily)
Ospemifene (oral SERM, 60 mg daily)
Both show meaningful improvements (roughly 30–80% depending on endpoint) in dyspareunia and dryness (Crandall et al., JAMA 2023).
4. Adjunctive Tools That Add Real Value
Pelvic floor physical therapy → especially with pain or muscle dysfunction
Vaginal hyaluronic acid → emerging evidence for symptom relief
Dilator therapy → underutilized but effective in select patients
Laser and energy-based therapies?
The evidence is still insufficient to recommend routine use.
Special Populations: Where Nuance Matters
Women with a history of breast cancer
Data on vaginal estrogen safety remain limited.
Management should include:
Shared decision-making
Coordination with oncology
Emphasis on nonhormonal therapies first
(Crean-Tate et al., AJOG 2020)
Older adults
The American Geriatrics Society recommends:
Avoid systemic estrogen
Favor local therapies (vaginal estrogen, DHEA) and nonhormonal options
(Beers Criteria update, 2025)
What Actually Moves the Needle in Practice
If there’s one takeaway, it’s this:
Recognition drives treatment. Treatment drives quality of life.
Actionable shifts you can implement immediately:
Add GSM screening to every menopausal visit
Normalize the conversation (“This is common and treatable”)
Start with education before escalation
Use local estrogen earlier when appropriate
Follow up—this is a chronic condition, not a one-time fix
The Bigger Picture
GSM sits at the intersection of endocrinology, urology, sexual health, and quality of life.
And yet, it often gets reduced to a footnote.
It shouldn’t be.
Because when treated effectively, the impact is immediate, meaningful, and often transformative for patients.
References
American College of Obstetricians and Gynecologists Practice Bulletin No. 213, 2019
Faubion SS et al. Mayo Clinic Proceedings. 2017
Crandall CJ et al. JAMA. 2023
North American Menopause Society (NAMS). 2020 Position Statement
Kaufman MR et al. Journal of Urology. 2025 (AUA/SUFU/AUGS Guideline)
Danan ER et al. Annals of Internal Medicine. 2024
Crean-Tate KK et al. American Journal of Obstetrics and Gynecology. 2020
Ringel NE et al. American Family Physician. 2020
Steinman MA. American Geriatrics Society Beers Criteria Update, 2025